Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

I just read something interesting, dolutegravir is

Message Board Public Reply | Private Reply | Keep | Replies (2)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154251
(Total Views: 316)
Posted On: 09/06/2019 5:08:52 PM
Avatar
Posted By: trding
I just read something interesting, dolutegravir is recommend for children by WHO. Dolutegravir attempted mono but the trial failed. It would seem the most logical choice to use leronimab first because it gives less side effects and is least likely to find resistance (their mono trial was cancelled because there was some resistance). I wonder if that is why the FDA asked for mono pediatric info for the Combo BLA, to use leronlimab as mono as the first or early option in kids... Seems a likely reason to me.

https://www.msf.org/pfizer-and-gsk%E2%80%99s-...d-medicine

Quote:


The World Health Organization (WHO) now recommends dolutegravir as a preferred treatment option for adults and for children from four weeks to ten years of age, to replace pediatric treatments containing sub-optimal drugs with more side effects. When starting treatment, children need access to the best and most robust medicines possible – which are least likely to result in resistance – given they will likely take HIV medicines for life.

Treating HIV and AIDS in Conakry
HIV/AIDS
MSF at AIDS 2018
Project Update 16 Jul 2018

“The nearly two million babies and kids around the world who live with HIV shouldn’t have to settle for inferior treatment when something better exists,” said Dr David Maman, medical coordinator for MSF in Malawi. “It’s outrageous that ViiV is dragging its feet when it comes to getting better treatment for children with HIV.”



(0)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us